Abstract
Objective: To determine the safety and effectiveness of blood donation in anemic patients, we harvested blood from cardiac patients with baseline hemoglobin levels below 11.0 g/dl.Methods: Subjects were 118 patients who underwent elective cardiac surgery between January 1994 and October 1997. We assigned patients to 1 of 2 groups based on their entry hemoglobin level: an anemic group (hemoglobin < 11.0 g/dl, n = 20) and a nonanemic group (hemoglobin ≧ 11.0 g/dl, n = 98). All patients received subcutaneous administration of recombinant human erythropoietin, and autologous blood was collected once a week for at least 3 weeks before the scheduled surgery date if the hemoglobin level exceeded 10.5 g/dl.Results: No statistically significant differences were seen between the 2 groups in patient profiles or surgical data. The estimated hemoglobin increase did not differ significantly between groups at any time point. The total collected blood volume per patient was greater in the nonanemic group than in the anemic group (1098 ± 224 ml vs. 712 ± 334 ml), but the difference in volume was not statistically significant The percentage of patients who received allogeneic blood did not differ significantly between groups. No side effects were associated with hemoglobin level prior to donation because the incidence of side effects was similar across hemoglobin levels.Conclusions: This study suggests that autologous blood donation reduces the need for allogeneic blood in patients with baseline hemoglobin levels below 11.0 g/dl.
Similar content being viewed by others
References
Levine EA, Rosen AL, Gould SA, Sehgal LR, Egrie JC, Browne JK, et al. Recombinant human erythropoietin and autologous blood donation. Surgery 1988; 104: 365–9.
Goodnough LT, Rundnick S, Price TH, Ballas SK, Collins ML, Crowley JP, et al. Increased preoperative collection of autologous blood donation with recombinant human erythropoietin therapy. N Engl J Med 1989; 321: 1163–8.
Goldberg MA. Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. Am J Surg 1995; 170: 37–43.
Hardy J-F, Belisle S, Janvier G, Samama M. Reduction in requirements for allogeneic blood products: nonpharmacologic methods. Ann Thorac Surg 1996; 62: 1935–43.
Janssens M, Hartstein G, David JL. Reduction in requirements for allogeneic blood products: pharmacologic methods. Ann Thorac Surg 1996; 62: 1944–50.
Cosgrove DM, Loop FD, Lytle BW, Gill CC, Golding LR, Taylor PC, et al. Determinants of blood utilization during myocardial revascularization. Ann Thorac Surg 1985; 40: 380–4
Paone G, Spencer T, Silverman NA. Blood conservation in coronary artery surgery. Surgery 1994; 116: 672–8.
Scott WJ, Rode R, Castlemain B, Kessler R, Follis F, Pett SB, et al. Efficacy, complications, and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg 1992; 103: 1001–7.
Watanabe Y, Fuse K, Naruse Y, Kobayashi T, Yamamoto S, Konishi H, et al. Subcutaneous use of erythropoietin in heart surgery. Ann Thorac Surg 1992; 54: 479–84.
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73–8.
Konishi T, Ohbayashi T, Kaneko T, Ohki T, Saito Y, Yamato Y. Preoperative use of erythropoietin for cardiovascular operations in anemia. Ann Thorac Surg 1993; 56: 101–3.
Sowade O, Warnke H, Scigalla P, Sowade B, Franke W, Messinger D, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 1997; 89: 411–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kiyama, H., Ohshima, N. & Imazeki, T. Safety and efficacy of blood donation prior to elective cardiac surgery in anemic patients. Jpn J Thorac Caridovasc Surg 48, 101–105 (2000). https://doi.org/10.1007/BF03218099
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03218099